tbuckley/cabot-search huggingface dataset:
GW27-e0264 A study on the mechanism of the inflammatory response in Ginsenoside Rb1 against the replicative senescence of endothelial cells
Authors: Bin Zhou, Xianguan Yu, Shujie Yu, Dinghui Liu, Min Wang, Lin Wu, Yong Liu, Baoshun Hao, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2016)
Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death
Authors: Matthew J. Scheffel, Gina Scurti, Patricia Simms, Elizabeth Garrett-Mayer, Shikhar Mehrotra, Michael I. Nishimura, Christina Voelkel-Johnson
Journal: Cancer Research (2016)

Abstract Although adoptive transfer of autologous tumor antigen–specific T-cell immunotherapy can produce remarkable clinical efficacy, most patients do not achieve durable complete responses. We hypothesized that reducing susceptibility of T cells to activation-induced cell death (AICD), which increases during the rapid in vitro expansion of therapeutic T cells before their infusion, might improve the persistence of adoptively transferred cells. Our investigations revealed that repetitive stimulation of the T-cell receptor (TCR) induced AICD, as a result of activating the DNA damage response pathway through ATM-mediated Ser15 phosphorylation of p53. Activation of this DNA damage response pathway also occurred upon antigen-specific restimulation in TCR-transduced TIL1383I T cells prepared for adoptive transfer to patients as part of a clinical trial. Notably, treatment with the antioxidant N-acetyl cysteine (NAC) significantly reduced upregulation of the DNA damage marker γH2AX, subsequent ATM activation, and cell death. In the Pmel mouse model of melanoma, the presence of NAC during ex vivo T-cell expansion improved the persistence of adoptively transferred cells, reduced tumor growth, and increased survival. Taken together, our results offer a preclinical proof of concept for the addition of NAC to current therapeutic T-cell expansion protocols, offering immediate potential to improve the quality and therapeutic efficacy of adoptive T-cell therapeutics infused into patients. Cancer Res; 76(20); 6006–16. ©2016 AACR.
Efficacy of capecitabine (C)-based therapy in patients with first-line metastatic breast cancer (MBC) previously treated with adjuvant anthracyclines and taxanes.
Authors: F. Siedentopf, W. Schoenegg, M. Kaufmann, M. Debled, N. J. Robert
Journal: Journal of Clinical Oncology (2010)

665 Background: Anthracyclines and taxanes are used increasingly in neoadjuvant and adjuvant chemotherapy (CT) in breast cancer. Consequently, MBC is frequently diagnosed in anthracycline- and/or taxane-pretreated pts. Retreatment with these agents is commonly compromised by resistance and/or cumulative toxicity. C is effective in the management of first-line MBC; the current analysis was undertaken to determine the first-line clinical efficacy of C in pts pretreated with adjuvant CT. Methods: 3 studies of C 1000 mg/m2, bid, d1-14 q3w, were included: a retrospective study of single-agent C (n=226; Debled et al 2009); a phase II study of single-agent C (n=161; Kaufmann et al 2009); a phase III, randomized study (RIBBON-1) of C ± bevacizumab (A; 15mg/kg, d1 q3w; n=615). Results: Prior exposure to neoadjuvant and adjuvant CT was reported in around 50-75% of pts. Of these, around 60-75% and 40-45% received anthracyclines or taxanes, respectively. Overall response rate (ORR) and CBR (CR+PR+SD) were around 25% and 60%, respectively (Table). In Debled et al, univariate analysis demonstrated similar time to treatment failure (TTF) in chemotherapy-naive and -pretreated pts (8.9 vs. 8.3 months; p=0.46). A similar analysis in RIBBON-1 supports a substantial benefit with C in chemotherapy-naïve and -pretreated pts (median PFS: 6.7 and 4.4 months, respectively), with consistent effects in taxane- (6.1 and 4.2 months) and anthracycline- pretreated pts (6.4 and 4.4 months). Notably, the addition of A appeared to overcome the effect of prior taxane exposure: CA median PFS 8.7 and 8.3 months in taxane-pretreated and -naïve pts, respectively. Conclusions: These data demonstrate that C consistently achieves improved clinical outcome in pts who have received prior neoadjuvant or adjuvant CT. Debled et al 2009 Kaufmann et al 2009 RIBBON-1 Study C (n=226) C (n=161) C (n=206) CA (n=409) Neoadjuvant or adjuvant CT, % 48 54 75.7 70.4 Anthracycline, % 39 35.8 69.4 60.4 Taxane, % 5 24.5 40.8 39.4 ORR, % 56 26.1 23.6 35.4 CBR, % 76 64 60.2 72.9 TTF, months 8.8 NR NR NR PFS, months NR 7.3* 5.7 8.6 * TTP Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Roche Roche
Syphilis infection throughout the whole gastrointestinal tract
Authors: Masami Ijiri, Mikihiro Fujiya, Nobuhiro Ueno, Shin Kashima, Tomohisa Watari, Satoshi Fujii, Toshikatu Okumura
Journal: Endoscopy (2016)

A 30-year-old Japanese woman presented to our hospital with epigastric pain. A physical examination revealed epigastric tenderness and red eruptions on her face. Laboratory evaluation showed normal results for leukocyte count and serum protein level, but a slightly elevated C-reactive protein (CRP) level of 1.10 mg/dL. The findings on serologic tests for syphilis, including rapid plasma regain and Treponema pallidum antibody hemagglutination test, were positive.
Use of Intravenous Busulphan for Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT) Is Associated with Delayed T-Cell Full Donor Chimerism and Lower Incidence of Acute Graft Versus Host Disease.
Authors: ZiYi Lim, Murugaiyan Thanigaikumar, Shreyans Gandhi, Laurence Pearce, Michelle Kenyon, Aloysius Y.L. Ho, Stephen Devereux, Antonio Pagliuca, Ghulam J. Mufti
Journal: Blood (2007)
Retrospective analysis of central venous catheter-related thrombosis in 427 cancer patients prophylaxed with low-dose warfarin
Authors: M. Magagnoli, G. Masci, L. Castagna, P. A. Zucali, V. Pedicini, S. Bramanti, M. Balzarotti, E. Morenghi, A. Santoro
Journal: Journal of Clinical Oncology (2004)

8102 Background: Cancer patients (pts) develop venous thrombosis more frequently than the general population; central venous catheters (CVC) insertion is a further risk factor. In this retrospective study, we analyzed whether low doses of warfarin are useful and safe in the thrombosis prophylaxis for cancer pts with CVC. Methods: Between July 2000 and May 2003, 427 pts (median age was 57 years; range 19–81) were evaluated. One hundred fifty-six (37%) pts had hematological malignancies. During warfarin prophylaxis, 142 pts received one (33%), 224 (52%) two, and 61 (15%) three or more chemotherapy regimens respectively. One hundred fifty-five pts (36%) underwent high-dose chemotherapy (HDT) followed by peripheral-blood-stem-cell transplantation (PBSCT). Three types of CVC were used throughout the study: 233 patients (54,5%) had an external device such as Vygon catheter, 167 (39%) had an external device such as Groshong Catheter, and 27 (6,5%) had a device completely internalized such as Port-a-cath. All pts received 1 mg/daily of oral warfarin from the day after CVC positioning until its removal. Results: The catheters were monitored for a mean of 168 days (range 22–706). There were 9 thrombotic events (1,8%). Of these, six events were observed in pts with haematological malignancies while one patient developed thrombosis during HDT. The median age was 40 years. The median number of days between line insertion and thrombosis was 152 (22–216). A number of potential predictive factors were analyzed for their impact on thrombotic events but no correlation was detected. Overall, International Normalized Ratio (INR) elevation occurred in 55 (12,8%) pts. Bleeding was observed in 15 (3,5%) pts, ten of whom had elevated INR levels. Of these, all were treated with regimens containing continuous-infusion 5-Fluorouracil (5-FU). Discussion: This large retrospective study shows that minidose warfarin can protect from clinical thrombosis. However an elevation of INR value associated to hemorrhagic symptoms can occur in pts treated with 5-FU-based regimens, suggesting a strict monitoring of these pts. No significant financial relationships to disclose.
TCT-229 Culprit versus Complete Multivessel Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction: Updated Meta-Analysis of Randomized Control Trials
Authors: Pedro A. Villablanca Spinetto, David Briceno, Marissa Lombardo, Daniele Massera, Anna Bortnick, Mark Menegus, Mario Garcia, Farouk Mookadam
Journal: Journal of the American College of Cardiology (2015)
TCT-567 Long-Term Outcomes With an Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent Versus a Cobalt-Chromium Everolimus-Eluting Stent in Single De Novo Coronary Lesions: Four-Year Results of the TARGET I Randomized Controlled Trial
Authors: Bo Xu, Changdong Guan, Yuejin Yang, Ma Changsheng, Yaling Han, Shao Liang Chen, Hui Li, Martin Leon, Run-Lin Gao
Journal: Journal of the American College of Cardiology (2015)
T-Cell Transcriptome Analysis Reveals the Mechanisms Controlling Synergy Between Costimulation Blockade and mTOR Inhibition during Graft Versus Host Disease Prevention
Authors: Scott N. Furlan, Benjamin Watkins, Kelly Hanby, Aneesah P. Garrett, Angela Panoskaltsis-Mortari, Bruce R. Blazar, Leslie S. Kean
Journal: Blood (2014)
Increase in ECHOvirus 6 infections associated with neurological symptoms in the Netherlands, June to August 2016
Authors: Kimberley SM Benschop, Felix Geeraedts, Barbara Beuvink, Silke A Spit, Ewout B Fanoy, Eric CJ Claas, Suzan D Pas, Rob Schuurman, Jaco J Verweij, Sylvia M Bruisten, Katja C Wolthers, Hubert GM Niesters, Marion Koopmans, Erwin Duizer
Journal: Eurosurveillance (2016)

The Dutch virus-typing network VIRO-TypeNed reported an increase in ECHOvirus 6 (E-6) infections with neurological symptoms in the Netherlands between June and August 2016. Of the 31 cases detected from January through August 2016, 15 presented with neurological symptoms. Ten of 15 neurological cases were detected in the same province and the identified viruses were genetically related. This report is to alert medical and public health professionals of the circulation of E-6 associated with neurological symptoms.
Human-Leukocyte-Histocompatibility Antigens (HLA-A1+, A2-, B44-) and Serum Immunoglobulin (Ig)G with CD4 Levels Predict Response to Graft-Versus-Leukemia (GVL) and Overall Survival, Respectively, After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL).
Authors: Issa F Khouri, Roland L Bassett, Pedro Cano, Susan O'Brien, Yvonne Hsu, Carlos E Bueso-Ramos, Robyn Harrell, Grace-Julia Okoroji, Leandro De Padua Silva, Alessandra Ferrajoli, William Wierda, Hagop Kantarjian, Richard Champlin, John McMannis, Marcelo Fernandez-Vina
Journal: Blood (2009)
TCT-588 Primary results of 2 years clinical investigation from en-ABL e-registry using novel abluminal coated sirolimus eluting stent with bio-degradable polymer matrix
Authors: Subhash Chandra, Sameer Dani, Prathap K. Natarajapillai, Devang M. Desai, Rashmit Pandya, Manish I. Doshi, Prakash N. Sojitra
Journal: Journal of the American College of Cardiology (2015)
Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment
Authors: Ming-Lung Yu, Chung-Feng Huang, Ming-Lun Yeh, Pei-Chien Tsai, Ching-I. Huang, Meng-Hsuan Hsieh, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang
Journal: Clinical Cancer Research (2016)

Purpose: Age and hepatic fibrosis are the factors that increase the risk of hepatocellular carcinoma over time. We aimed to explore their impact at the initiation of antiviral therapy on hepatocellular carcinoma among chronic hepatitis C (CHC) patients.Experimental Design: A total of 1,281 biopsy-proven CHC patients receiving IFN-based therapy were followed for a mean period of 5.5 years.Results: The 5-year cumulative incidence of hepatocellular carcinoma did not differ between non-sustained virological response (SVR) and SVR patients who were <40 years old (7.7% vs. 0.5%, P = 0.1) but was significantly higher in non-SVR patients between 40 and 55 years old (18.0% vs. 1.3%, P < 0.001) and >55 years old (15.1% vs. 7.9%, P = 0.03). Compared with SVR, non-SVR was independently predictive of hepatocellular carcinoma in patients 40 to 55 years old [HR/95% confidence intervals (CI), 10.92/3.78-31.56; P < 0.001] and >55 years old (HR/CI, 1.96/1.06-3.63; P = 0.03) but not in patients <40 years old (HR/CI, 2.76/0.41-18.84; P = 0.3). The 5-year cumulative incidence of hepatocellular carcinoma did not differ between non-SVR and SVR patients whose fibrosis stage was F0-1 (4.6% vs. 1.9%, P = 0.25) but was higher in non-SVR patients with F2-3 (21.4% vs. 4.3%, P < 0.001) or F4 (33.5% vs. 8.4%, P = 0.002). Compared with SVR, non-SVR was independently predictive of hepatocellular carcinoma in patients with F2-3 (HR/CI, 4.36/2.10-9.03; P < 0.001) and F4 (HR/CI, 3.84/1.59-9.30; P = 0.03) but not in those with F0-1 (HR/CI, 1.53/0.49-4.74; P = 0.47).Conclusions: Delayed hepatitis C virus clearance for patients with CHC >40 years old or with a fibrosis stage >2 increases the risk of hepatocellular carcinoma over time. Clin Cancer Res; 23(7); 1690-7. ©2016 AACR.
Methylation of the PTPNS1 Promoter Region in Pediatric Acute Promyelocytic Leukemia.
Authors: Isabelle Hubeek, Jacqueline Cloos, Ellen M. van Beek, Richard Broekhuizen, Arjan A. Van de Loosdrecht, Michel Zwaan, Brian Balgobind, Timo K. van den Berg, Gertjan J. Kaspers
Journal: Blood (2007)
REP Regimen (Rituximab, Erythropoietin and Prednisone) in the Treatment of Refractory Autoimmune Hemolytic Anemia (R-AIHA).
Authors: Francesco Iuliano, Massimo Di Maio, Stefania Infusino, Alessia Perricelli, Angelo Pomillo, Antonio Russo, Amalia Giuliano, Vincenzo Pata
Journal: Blood (2008)
Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results.
Authors: Luigi Gugliotta, S. Bulgarelli, S. Asioli, A. Tieghi, G. Gardini, E. Sabattini, V. Franco, E. Boveri, H. M. Kvasnicka, N. Vianelli, A. Candoni, R. Latagliata, F. Passamonti, S. Rupoli, V. Martinelli, A. Zaccaria, F. Lauria, E. De Biasi, S. Sacchi, M. Gobbi, A. Tabilio, E. Cacciola, R. Cacciola, A. Grossi, P. Mazza, F. Bonifazi, P. Favini, F. Mandelli, M. Baccarani, J. Thiele
Journal: Blood (2005)
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53,
Authors: Carolina Terragna, Marina Martello, Sandra Durante, Lucia Pantani, Elena Zamagni, Paola Tacchetti, Annamaria Brioli, Giulia Perrone, Beatrice Anna Zannetti, Enrica Borsi, Michele Baccarani, Giovanni Martinelli, Michele Cavo
Journal: Blood (2011)
TCT-623 Transcatheter Aortic Valve Replacement In Women Versus Men: An Analysis of the CoreValve US Pivotal and Continued Access Trials
Authors: John K. Forrest, Alexandra Lansky, Brij Maini, Kimberly A. Skelding, Alfred Casale, Peter S. Fail, Jeffrey Popma
Journal: Journal of the American College of Cardiology (2015)
TCT-293 Intracoronary Adenosine: Dose-Response Relationship with Hyperemia
Authors: Julien Adjedj, Gabor G. Toth, Nils P. Johnson, Mariano Pellicano, Angela Ferrara, Vincent Floré, Giuseppe Di-Gioia, Emanuele Barbato, Olivier Muller, Bernard De Bruyne
Journal: Journal of the American College of Cardiology (2015)
The nasal methylome and childhood atopic asthma
Authors: Ivana V. Yang, Brent S. Pedersen, Andrew H. Liu, George T. O'Connor, Dinesh Pillai, Meyer Kattan, Rana Tawil Misiak, Rebecca Gruchalla, Stanley J. Szefler, Gurjit K. Khurana Hershey, Carolyn Kercsmar, Adam Richards, Allen D. Stevens, Christena A. Kolakowski, Melanie Makhija, Christine A. Sorkness, Rebecca Z. Krouse, Cynthia Visness, Elizabeth J. Davidson, Corinne E. Hennessy, Richard J. Martin, Alkis Togias, William W. Busse, David A. Schwartz
Journal: Journal of Allergy and Clinical Immunology (2016)
Hematopoietic Cell Transplantation as Therapy for Pediatric Patients with Relapsed Acute Lymphoblastic Leukemia with and without CNS Involvement.
Authors: Paul D. Harker-Murray, Michael R. Verneris, Avis J. Thomas, Xianghua Luo, Margaret L. MacMillan, Jakub Tolar, K. Scott Baker, John E. Wagner, Paul J. Orchard
Journal: Blood (2006)
TCT-107 The DISCOVER Registry: 1 Year outcomes of a fully re-positionable and retrievable non-metallic transcatheter aortic valve in a real-world population
Authors: Federico De Marco, Christoph Naber, Hüseyin Ince, Daniel Wagner, Antonio Colombo, Christian Butter, Didier Tchetche, Fernando Gatto, Ulrich Hink, Martine Gilard, Giuseppe Bruschi, Georg Nickenig, Guus Brueren, Thierry Lefevre, Smita Scholtz, Wolfgang Schillinger, Peter den Heijer, Jan Van der Heyden, Hervé Le Breton, Karl-Heinz Kuck, Joachim Schofer, Dimitar Divchev, Federico M. Asch, Azeem Latib, Peter Frambach, Stephan Kische
Journal: Journal of the American College of Cardiology (2015)
Phase I/II study of metronomic chemotherapy using S-1 and irinotecan in patients with advanced colorectal cancer (KSCOG CR-01)
Authors: Y. Ogata, Y. Akagi, T. Sasatomi, S. Mori, N. Ishibashi, K. Shiouzu, T. Tanaka, Y. Tsuji, S. Sueyoshi, M. Isobe
Journal: Journal of Clinical Oncology (2008)

2535 Background: The antiangiogenic efficacy of chemotherapy would seem to be optimized by administering comparatively lower dosages of drugs on a more frequent (daily, several times a week, or weekly) or continuous schedule, with no extended interruptions, sometimes referred to as ‘metronomic’ chemotherapy. This phase I/II study determine the recommended dose (RD), the efficacy and safety of the metronomic chemotherapy using oral fluoropyrimidine S-1 plus weekly irinotecan (CPT-11) in patients with previously untreated advanced or recurrent colorectal cancer. Methods: Patients received first-line chemotherapy comprising S-1 80 mg/m(2)/day given on days 3 to 7, 10 to 14, and 17 to 21 with escalating doses of CPT-11 (from 40 mg/m(2)) administered intravenously on day 1, 8, and 15 of a 28-day cycle. Eligibility criteria were standard. Patients were assigned on the basis of body surface area (BSA) to receive one of the following oral doses of S-1 twice daily: 40 mg (BSA < 1.25 m(2)), 50 mg (BSA ≥ 1.25 to < 1.50 m(2)), or 60 mg (BSA ≥ 1.50 m(2)). The RD was defined as the dose at which ≥ 50% of six patients experienced a skip of CPT-11 or S-1 during cycle 1 within the MTD. Results: The 60 mg/m (2) dose level was established as the RD of CPT-11 and expanded to 45 patients in whom treatment was generally well tolerated with a 92% in CPT-11 and a 95% in S-1 as dose intensity. One patient had complete response, and 21 had partial responses. The overall response rate was 48.9% (95% confidential interval, 33.7%-64.2%). Median progression-free survival was 7.6 months. The rates of grade 3 or 4 toxicity were as follows: neutropenia, 8.9%; anemia, 4.4%; anorexia, 6.7%; and diarrhea, 4.4%. Conclusions: Metronomic chemotherapy using S-1 and irinotecan is an effective, less toxic, and convenient regimen in patients with advanced colorectal cancer. Our findings suggest that this metronomic chemotherapy is a promising regimen, offering benefits in terms of safety and survival as compared with conventional regimens in patients with advanced colorectal cancer. No significant financial relationships to disclose.
GW27-e0470 Mutations in SCAP and AGXT2 Revealed by Exome Sequencing in a Pedigree with Premature Myocardial Infarction
Authors: Gao Yuanfeng, Junxian Song, Sufang Li, Yuxia Cui, Chongyou Lee, Hong Chen
Journal: Journal of the American College of Cardiology (2016)
Visits to urologists and radiation oncologists prior to treatment decision making for clinically localized prostate cancer (LCaP)
Authors: T. L. Jang, J. E. Bekelman, Y. Liu, P. B. Bach, E. M. Basch, E. B. Elkin, M. J. Zelefsky, P. T. Scardino, C. B. Begg, D. Schrag
Journal: Journal of Clinical Oncology (2007)

6506 Background: The two primary therapies for LCaP are delivered by different types of physicians, urologists and radiation oncologists. We evaluated how visits to various specialists relate to treatment choice. Methods: Using data from the Surveillance, Epidemiology and End Results (SEER)-Medicare linked program, we evaluated 85,088 men with LCaP aged 65 and older diagnosed between 1994 and 2002 who received either radical prostatectomy (n=18,201), radiotherapy (n=35,925), primary androgen deprivation therapy (n=14,021), or expectant management (n=16,941) within 9 months of diagnosis. Prostate cancer specialists were identified by Medicare claims or data from the AMA Physician Masterfile. Results: Table 1 shows a strong association between the different specialists consulted and primary therapy received. When men aged 65 to 69 saw only a urologist, 70% had a radical prostatectomy; when also seen by a radiation oncologist, 15% had a radical prostatectomy. We found greater than expected variation in the propensity of a particular urologist’s patients to undergo radiotherapy evaluation, suggesting that some men are seen by a radiation oncologist less frequently (and others more frequently) than would be explained by chance. Conclusions: Recognizing that prostate cancer specialists have different viewpoints on the most appropriate management strategy, it is imperative to ensure that all men have access to balanced information prior to definitive therapy. No significant financial relationships to disclose. [Table: see text]
Impaired Antibody RESPONSE FOLLOWING VACCINATION Against Hepatitis-B VIRUS In Autografted PATIENTS for Hematologic Malignancies: PRELIMINARY RESULTS
Authors: Panayotis Kaloyannidis, Varnavas Konstantinou, Elisavet Georgiadou, Fani Zervou, Ioannis Batsis, Despina Mallouri, Evangelia Yannaki, Maria Papathanasiou, Aliki Xoheli, Ioanna Sakellari, George Kiriazis, Achilles Anagnostopoulos
Journal: Blood (2011)
TCT-350 Coronary Plaque Progression as Assessed by Intravascular Ultrasound after Cardiac Transplantation Is Decreased with Use of Antithymocyte Globulin Induction Therapy in a Dose-Dependent Manner
Authors: Richard Cheng, Babak Azarbal, Christopher T. Vanichsarn, Jignesh Patel, David Chang, Jon Kobashigawa
Journal: Journal of the American College of Cardiology (2015)
GW27-e0765 The serial platelet function testing among patients with complex coronary lesion predicts long-term outcomes after drug-eluting stents implantation
Authors: Mengmeng Li, Quan Li, Xuejun Ren, Xianpeng Yu, Jiqiang He, Yuechun Gao, Xiaoling Zhang, Changyan Wu, Yawei Luo, Yuchen Zhang, Fang Chen
Journal: Journal of the American College of Cardiology (2016)
Phase I Study of mTOR Inhibitor Everolimus Plus CHOP in Patients with Advanced, Aggressive T-Cell lymphomas
Authors: Seok Jin Kim, Hye Jin Kang, Jin Seok Kim, Hyeon-Seok Eom, Jooryung Huh, Young Hyeh Ko, Dong-Seok Yim, Soo-Youn Lee, Cheolwon Suh, Won Seog Kim
Journal: Blood (2011)
High Incidence of Primary Resistance to Imatinib in the Group of Ph-Negative BCR-ABL-positive CML Patients,
Authors: Grigory Tsaur, Olga Plekhanova, Alexander Popov, Tatyana Riger, Anna Ivanova, Yulia Gryaznova, Ekaterina Nokhrina, Bulat Bakirov, Irina Krylova, Sergey Meresiy, Marina Shumkova, Egor Shorikov, Leonid Saveliev, Larisa Fechina
Journal: Blood (2011)